Search

Your search keyword '"Board R"' showing total 378 results
Start Over Author "Board R"
378 results on '"Board R"'

6. Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme

Author

Challapalli, A., primary, Watkins, S., additional, Cogill, G., additional, Stewart, G., additional, Ellis, S., additional, Sykes, A., additional, Nobes, J., additional, Yip, K., additional, Barthakur, U., additional, Board, R., additional, Gadve, A., additional, O’Toole, L., additional, Kent, C., additional, Mackenzie, J., additional, Papa, S., additional, Fusi, A., additional, and Fife, K., additional

Published
2022
Full Text
View/download PDF

9. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Author

Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, and Gee, B

Subjects
Oncology, 0301 basic medicine, Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, Dermatologic Surgical Procedures, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Clinical endpoint, Melanoma, Aged, 80 and over, Manchester Cancer Research Centre, Hazard ratio, adjuvant therapy, Hematology, Middle Aged, Corrigenda, Vascular endothelial growth factor, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Bevacizumab, Adolescent, bevacizumab, Disease-Free Survival, Drug Administration Schedule, RC0254, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Adjuvant therapy, melanoma, Humans, Watchful Waiting, Survival analysis, Aged, Neoplasm Staging, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Original Articles, medicine.disease, Survival Analysis, Confidence interval, 030104 developmental biology, chemistry, Mutation, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. Results Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). Conclusions Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. Clinical Trial Information ISRCTN 81261306; EudraCT Number: 2006-005505-64

Published
2018

14. Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study

Author

Dalle, S., primary, Mortier, L., additional, Corrie, P., additional, Lotem, M., additional, Board, R., additional, Arance, A.M., additional, Meiss, F., additional, Terheyden, P., additional, Gutzmer, R., additional, Brokaw, J., additional, Le, T.K., additional, Mathias, S.D., additional, Scotto, J., additional, Lord-Bessen, J., additional, Moshyk, A., additional, Kotapati, S., additional, and Middleton, M.R., additional

Published
2019
Full Text
View/download PDF

18. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.

Author

Copson E., Dark G., Eccles D., Gallagher C., Glaser A., Griffiths R., Hall G., Hall M., Harari D., Hawkins M., Hill M., Johnson P., Kalsi T., Karapanagiotou E., Kemp Z., Mansi J., Marshall E., Mitchell A., Moe M., Michie C., Neal R., Newsom-Davis T., Norton A., Osborne R., Patel G., Radford J., Ring A., Shaw E., Skinner R., Stark D., Turnbull S., Velikova G., White J., Young A., Joffe J., Selby P., Jones A., Baird R., Banks I., Cameron D., Chester J., Earl H., Flannagan M., Januszewski A., Kennedy R., Payne S., Samuel E., Taylor H., Agarwal R., Ahmed S., Archer C., Board R., Carser J., Cunningham D., Coleman R., Dangoor A., Copson E., Dark G., Eccles D., Gallagher C., Glaser A., Griffiths R., Hall G., Hall M., Harari D., Hawkins M., Hill M., Johnson P., Kalsi T., Karapanagiotou E., Kemp Z., Mansi J., Marshall E., Mitchell A., Moe M., Michie C., Neal R., Newsom-Davis T., Norton A., Osborne R., Patel G., Radford J., Ring A., Shaw E., Skinner R., Stark D., Turnbull S., Velikova G., White J., Young A., Joffe J., Selby P., Jones A., Baird R., Banks I., Cameron D., Chester J., Earl H., Flannagan M., Januszewski A., Kennedy R., Payne S., Samuel E., Taylor H., Agarwal R., Ahmed S., Archer C., Board R., Carser J., Cunningham D., Coleman R., and Dangoor A.

Abstract

The Association of Cancer Physicians in the United Kingdom has developed a strategy to improve outcomes for cancer patients and identified the goals and commitments of the Association and its members.

Published
2016

23. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE)

Author

Middleton, M., primary, Dalle, S., additional, Corrie, P., additional, Loquai, C., additional, Terheyden, P., additional, Kähler, K.C., additional, Meiss, F., additional, Board, R., additional, Arance, A.M., additional, Gutzmer, R., additional, Tarhini, A., additional, Dummer, R., additional, Ernst, S., additional, Richtig, E., additional, Wolter, P., additional, Bulger, K., additional, Kotapati, S., additional, Le, T.K., additional, Brokaw, J., additional, and Abernethy, A.P., additional

Published
2015
Full Text
View/download PDF

36. School-age children's perceptions of their PICU hospitalization. (Research Oral Presentations)

Author

Board, R

Subjects
Critically ill children -- Surveys -- Beliefs, opinions and attitudes, Hospital patients -- Surveys -- Beliefs, opinions and attitudes, Pediatric intensive care -- Research -- Surveys, Health, Health care industry, Beliefs, opinions and attitudes, Research, Surveys
Abstract

Research Oral Abstract Award Winner Purpose: The overall aim of this descriptive study was to explore the effects of a PICU hospitalization on critically ill school-age children. Background/Significance: Hospitalization is [...]

Published
2003

42. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.

Author

Khoja, L, Backen, A, Sloane, R, Menasce, L, Ryder, D, Krebs, M, Board, R, Clack, G, Hughes, A, Blackhall, F, Valle, J W, and Dive, C

Subjects
PANCREATIC cancer diagnosis, TUMORS, TUMOR markers, HIGH throughput screening (Drug development), CANCER patients, CELL adhesion molecules
Abstract

Background:Obtaining tissue for pancreatic carcinoma diagnosis and biomarker assessment to aid drug development is challenging. Circulating tumour cells (CTCs) may represent a potential biomarker to address these unmet needs. We compared prospectively the utility of two platforms for CTC enumeration and characterisation in pancreatic cancer patients in a pilot exploratory study.Patients and methods:Blood samples were obtained prospectively from 54 consenting patients and analysed by CellSearch and isolation by size of epithelial tumour cells (ISET). CellSearch exploits immunomagnetic capture of CTCs-expressing epithelial markers, whereas ISET is a marker independent, blood filtration device. Circulating tumour cell expression of epithelial and mesenchymal markers was assessed to explore any discrepancy in CTC number between the two platforms.Results:ISET detected CTCs in more patients than CellSearch (93% vs 40%) and in higher numbers (median CTCs/7.5 ml, 9 (range 0-240) vs 0 (range 0-144)). Heterogeneity observed for epithelial cell adhesion molecule, pan-cytokeratin (CK), E-Cadherin, Vimentin and CK 7 expression in CTCs may account for discrepancy in CTC number between platforms.Conclusion:ISET detects more CTCs than CellSearch and offers flexible CTC characterisation with potential to investigate CTC biology and develop biomarkers for pancreatic cancer patient management. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results